Use of an anti-cd151 antibody in the treatment of cancer

Abstract

The present invention relates to the use of at least one antibody, or a functional fragment thereof, which is capable of binding to the CD151 protein and thereby inhibiting tumour growth, in the preparation of a medicament intended for the treatment of cancer. The invention is also directed to a composition for the treatment of cancer, comprising, as active ingredient, at least one anti-CD151 antibody, or a functional fragment thereof, which is capable of binding to the CD151 protein and/or of inhibiting the development of primary tumours and/or of inhibiting its metastasis-promoting activity, which antibodies may consist of the antibodies TS151 and/or TS151r.

1 . A composition for the treatment of cancers which overexpress a human CD151 protein, comprising as an active ingredient, at least one anti-CD151 antibody which binds to the human CD151 protein, whereby the at least one anti-CD151 antibody inhibits the development of primary tumors. 
     
     
         2 . The composition of  claim 1 , wherein the at least one anti-CD151 antibody inhibits primary tumor growth. 
     
     
         3 . The composition of  claim 1 , wherein the at least one anti-CD151 antibody inhibits primary tumor cell proliferation. 
     
     
         4 . The composition of  claim 1 , wherein the at least one anti-CD151 antibody inhibits tumor cell migration. 
     
     
         5 . The composition of  claim 1 , wherein the at least one anti-CD151 antibody inhibits cell invasion by tumor cells. 
     
     
         6 . The composition of  claim 1 , wherein the at least one anti-CD151 antibody inhibits tumor cell adhesion. 
     
     
         7 . The composition of  claim 1 , wherein the at least one anti-CD151 antibody binds to an epitope on the extracellular loop 2 (EC2) region comprising, at least, the amino acids Glutamine, Arginine and Aspartic Acid at positions 194, 195 and 196 (QRD 194-196 ), respectively, of the CD151 protein. 
     
     
         8 . The composition of  claim 1 , wherein the at least one anti-CD151 antibody is a monoclonal antibody. 
     
     
         9 . The composition of  claim 1 , wherein the at least one anti-CD151 antibody is a binding fragment selected from Fv, scFv, Fab, F(ab′) 2 , F(ab′) and scFv-Fc. 
     
     
         10 . The composition of  claim 1 , wherein the at least one anti-CD151 antibody is a TS151 antibody. 
     
     
         11 . The composition of  claim 10 , wherein the TS151 antibody comprises:
 three heavy-chain complementarity determining regions, CDR-H1 (SEQ ID NO: 7), CDR-H2 (SEQ ID NO: 8) and CDR-H3 (SEQ ID NO. 9); and   three light-chain complementarity determining regions, CDR-L1 (SEQ ID NO: 11), CDR-L2 (SEQ ID NO: 12) and CDR-L3 (SEQ ID NO: 13).   
     
     
         12 . The composition of  claim 11 , wherein the TS151 antibody comprises:
 a heavy chain further comprising the sequence SEQ ID No. 10, and/or   a light chain further comprising the sequence SEQ ID No. 14.   
     
     
         13 . The composition of  claim 1 , wherein the at least one anti-CD151 antibody is a TS151r antibody. 
     
     
         14 . The composition of  claim 13 , wherein the TS151r antibody comprises:
 three heavy-chain complementarity determining regions, CDR-H1 (SEQ ID NO: 15), CDR-H2 (SEQ ID NO: 16) and CDR-H3 (SEQ ID NO. 17); and   three light-chain complementarity determining regions, CDR-L1 (SEQ ID NO: 19), CDR-L2 (SEQ ID NO: 20) and CDR-L3 (SEQ ID NO: 21).   
     
     
         15 . The composition of  claim 13 , wherein the TS151r antibody comprises:
 a heavy chain further comprising the sequence SEQ ID No. 18, and/or   a light chain further comprising the sequence SEQ ID No. 22.   
     
     
         16 . The composition of  claim 1 , wherein the at least one anti-CD151 antibody which binds to the human CD151 protein is selected from a TS151 antibody, a TS151r antibody and combinations thereof. 
     
     
         17 . The composition of  claim 1 , which is administered to a human or animal subject in an amount effective for the treatment of cancers which overexpress a human CD151 protein. 
     
     
         18 . The composition of  claim 1 , which is administered to a human or animal subject in an amount effective for the treatment of colon cancer. 
     
     
         19 . The composition of  claim 1 , which is administered to a human or animal subject in an amount effective for the treatment of lung cancer. 
     
     
         20 . The composition of  claim 1 , which is administered to a human or animal subject in an amount effective for the treatment of prostate cancer. 
     
     
         21 . The composition of  claim 1 , which is administered to a human or animal subject in an amount effective for the treatment of pancreatic cancer. 
     
     
         22 . The composition of  claim 1 , which is administered to a human or animal subject in an amount effective for the treatment of primary tumors. 
     
     
         23 . The composition of  claim 1  further comprising at least one pharmaceutically acceptable carrier.